Gentronix and Apredica Ally to Create Predictive-Toxicology Service
News Jun 11, 2009
Gentronix Limited, a genotoxicity product and services provider, and Apredica, an ADME-Tox contract research laboratory, have announced a strategic alliance to provide drug-discovery support services in the area of predictive toxicology.
The objective of the alliance is to reduce the failure rate of drugs in late development, particularly due to toxicity, thereby improving the efficiency of drug discovery and increasing assurance that new drugs are safe.
“Gentronix and Apredica have worked closely together for over a year,” said Dr Katya Tsaioun, President of Apredica. “We have developed a joint predictive toxicology offering based on a set of assays that accurately predict many known mechanisms of human toxicities.” In addition to the joint service offering, UK-based Gentronix and US-based Apredica have also agreed to become mutual agents.
The alliance offers a new suite of predictive in vitro toxicology services to help improve the speed and efficiency of drug development. Commenting on the announcement, John Nicholson, Chairman and CEO of Gentronix said: “Early prediction of genotoxicity and attrition-rate improvement is critical to the success of drug discovery. Our alliance with Apredica allows our customers to concentrate resources on compounds most likely to succeed in development, and to select the best candidates for clinical trials sooner."
Drug discovery and development programs see many drug candidates fail in clinical-trial stages, which are the most costly and time-consuming stages of drug development.
Reducing attrition rates in drug development, especially the later stages of development, is critical to increasing the success and efficiency of drug discovery. Identifying problems with new chemical entities as early as possible allows resources to be directed towards chemistries with greater propensities to advance to candidate selection and on to clinical evaluation.